



Commonwealth of Massachusetts  
**MassHealth Drug Utilization Review Program**  
 P.O. Box 2586, Worcester, MA 01613-2586  
**Fax:** (877) 208-7428      **Phone:** (800) 745-7318

## Antidepressant Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about antidepressants and the **Pediatric Behavioral Health Medication Initiative**, including PA requirements, a complete list of all behavioral health medications, and preferred products, can be found within the MassHealth Drug List at [www.mass.gov/druglist](http://www.mass.gov/druglist). The related PA form is available at: **Pediatric Behavioral Health Medication Initiative PA Request Form**.

### Member information

Last name \_\_\_\_\_ First name \_\_\_\_\_ MI \_\_\_\_\_  
 MassHealth member ID # \_\_\_\_\_ Date of birth \_\_\_\_\_  
 Gender (Check one.)  F  M      Member's place of residence  home  nursing facility

### Medication information

#### Medication requested

- |  |   |   |
|--|---|---|
| <input type="checkbox"/> Aplenzin (bupropion hydrobromide extended-release) > 1 unit/day | <input type="checkbox"/> Drizalma (duloxetine sprinkle capsule)   | <input type="checkbox"/> olanzapine/fluoxetine                |
| <input type="checkbox"/> bupropion XL > 1 unit/day                                       | <input type="checkbox"/> duloxetine 40 mg capsule                 | <input type="checkbox"/> paroxetine controlled-release        |
| <input type="checkbox"/> bupropion hydrochloride extended-release 450 mg tablet          | <input type="checkbox"/> Emsam (selegiline)                       | <input type="checkbox"/> Pexeva (paroxetine mesylate)         |
| <input type="checkbox"/> clomipramine  | <input type="checkbox"/> Fetzima (levomilnacipran) > 1 unit/day   | <input type="checkbox"/> protriptyline                        |
| <input type="checkbox"/> desipramine   | <input type="checkbox"/> fluoxetine 60 mg tablet                  | <input type="checkbox"/> Spravato (esketamine)                |
| <input type="checkbox"/> desvenlafaxine extended-release                                 | <input type="checkbox"/> fluoxetine 90 mg delayed-release capsule | <input type="checkbox"/> trazodone 300 mg tablet              |
| <input type="checkbox"/> desvenlafaxine succinate extended-release > 1 unit/day          | <input type="checkbox"/> fluvoxamine extended-release             | <input type="checkbox"/> trimipramine                         |
|  | <input type="checkbox"/> imipramine pamoate tablet                | <input type="checkbox"/> Trintellix (vortioxetine)            |
|  | <input type="checkbox"/> maprotiline                              | <input type="checkbox"/> venlafaxine extended-release tablets |
|  | <input type="checkbox"/> Marplan (isocarboxazid)                  | <input type="checkbox"/> Viibryd (vilazodone)                 |
|  | <input type="checkbox"/> mirtazapine orally disintegrating tablet | <input type="checkbox"/> Zulresso (brexanolone)^              |
|  |   | <input type="checkbox"/> Other* _____                         |

\* If request is for a non-preferred brand name or generic product, please attach supporting documentation (e.g., copies of medical records and/or office notes regarding adverse reaction or inadequate response to the preferred product).

^ This drug is available through the health care professional who administers the drug. MassHealth does not pay for this drug to be dispensed through a retail pharmacy.

**Dose, frequency, and duration of medication requested** \_\_\_\_\_

Drug NDC (if known) \_\_\_\_\_

#### Indication (Check all that apply.)

- |  |  |
|--|--|
| <input type="checkbox"/> Major depressive disorder     | <input type="checkbox"/> Panic disorder        |
| <input type="checkbox"/> Obsessive-compulsive disorder | <input type="checkbox"/> Postpartum depression |

Premenstrual dysphoric disorder

Other (describe) \_\_\_\_\_

Please list all other psychotropic medications currently prescribed for the member.

Has member been hospitalized for this condition?

Yes. Dates of most recent hospitalization \_\_\_\_\_  No

Is the member under the care of psychiatrist?  Yes  No

Name of psychiatrist \_\_\_\_\_

Telephone no. \_\_\_\_\_ Date of last visit or consult with psychiatrist \_\_\_\_\_

Is this member a referral candidate for care coordination?  Yes  No

If yes, MassHealth will offer this member care coordination services. Please describe which additional behavioral health services would be beneficial.

---

**Section I. Please complete for bupropion hydrochloride extended-release 450 mg tablet, desvenlafaxine extended-release, duloxetine 40 mg capsule, fluoxetine 60 mg tablet, fluoxetine 90 mg delayed-release capsule, fluvoxamine extended-release, imipramine pamoate, paroxetine controlled-release, Pexeva, trazodone 300 mg tablet, and venlafaxine extended-release tablet.**

Please attach medical records documenting an inadequate response (defined as at least four weeks of therapy) or adverse reaction to the respective formulation of the agent requested that is available without prior authorization. For Pexeva, in addition attach medical records of paroxetine controlled-release trial.

---

**Section II. Please complete for requests for clomipramine, desipramine, maprotiline, Marplan, protriptyline, trimipramine, Trintellix, and Viibryd.**

Please describe applicable antidepressant trials and outcomes (attach a letter with additional information regarding trials as applicable).

Drug name \_\_\_\_\_ Dates/duration of use \_\_\_\_\_ Dose and frequency \_\_\_\_\_

Did member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name \_\_\_\_\_ Dates/duration of use \_\_\_\_\_ Dose and frequency \_\_\_\_\_

Did member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

---

**Section III. Please complete for requests for Emsam.**

1. Has the member had a trial with one SSRI and one non-SSRI antidepressant?

Yes. Please list the drug name, dose and frequency, dates/duration of trials, and outcomes below.

Drug name \_\_\_\_\_ Dates/duration of use \_\_\_\_\_ Dose and frequency \_\_\_\_\_

Did the member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name \_\_\_\_\_ Dates/duration of use \_\_\_\_\_ Dose and frequency \_\_\_\_\_

Did the member experience any of the following?  Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

No. Please explain why not. \_\_\_\_\_

2. Is there a medical necessity for the transdermal formulation?  Yes  No

If yes, please explain. \_\_\_\_\_

---

**Section IV. Please complete for requests for Drizalma and mirtazapine orally disintegrating tablet.**

Is there a medical necessity for the specific dosage form?

Yes. Please explain. \_\_\_\_\_

No. If the request is for mirtazapine orally disintegrating tablet, please attach medical records documenting an inadequate response (defined as at least four weeks of therapy) or adverse reaction to mirtazapine tablet.

---

**Section V. Please complete for requests for olanzapine/fluoxetine.**

Please describe the medical necessity for use of the combination product instead of the commercially available separate agents. \_\_\_\_\_

---

**Section VI. Please complete for requests for Spravato.**

For requests for treatment resistant depression, please complete questions 1, 2, and 4. Initial requests for major depressive disorder with acute suicidal ideation or behavior, please complete questions 3 and 4. Subsequent requests for major depressive disorder with acute suicidal ideation or behavior should complete the questions for treatment resistant depression.

1. Please attach medical records documenting a trial with one SSRI and one non-SSRI antidepressant.
2. Please attach medical records documenting a trial with one of the following antidepressant augmentation strategies: second-generation antipsychotic, lithium, a second antidepressant from a different class, thyroid hormone. If there is a contraindication to all antidepressant augmentation strategies, attach medical records documenting the contraindication.
3. Please attach medical records documenting either current acute suicidal ideation or behavior related to depressive symptoms of major depressive disorder, or that the member was stabilized on esketamine during a psychiatric hospitalization.
4. Will the requested agent be used in combination with an oral antidepressant?  Yes  No

---

**Section VII. Please complete for requests for Aplenzin > 1 unit/day, bupropion XL > 1 unit/day, desvenlafaxine succinate extended-release > 1 unit/day or Fetzima > 1 unit/day.**

Has dose consolidation been attempted?  Yes  No. Please describe medical necessity for quantities above 30 units/month. \_\_\_\_\_

---

**Section VIII. Please complete for requests for Zulresso.**

1. Is the member pregnant?  Yes  No. Please document date of delivery. \_\_\_\_\_
2. Please document date of onset of major depressive episode(s). \_\_\_\_\_
3. Member's current weight \_\_\_\_\_ Date \_\_\_\_\_

---

**Section IX. Antidepressant Polypharmacy for members ≥ 18 years of age. Please complete information for medications requested and select the reason for polypharmacy with antidepressants (two or more SSRI, SNRI, or Serotonin Modulator antidepressants for ≥ 60 days within a 90-day period).**

1. Antidepressant name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
2. Antidepressant name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_

over

3. Antidepressant name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_

Please document clinical rationale for polypharmacy within the same medication class for this member.

---

---

**Section X. Please complete for all requests for non-preferred drug products if one or more preferred drug products have been designated for this class of drugs.**

If one or more preferred drug products have been designated for this class of drugs, and if you are requesting PA for a non-preferred drug product, please provide medical necessity for prescribing the non-preferred drug product rather than the preferred drug product.

---

---

**MassHealth Pediatric Behavioral Health Medication Initiative**

**Please fill out all the sections below, as applicable, for pediatric members only. You may also use the Pediatric Behavioral Health Medication Initiative PA Request Form if the member is prescribed other behavioral health medications.**

---

**Section I. Please complete for all requests for medications subject to the Pediatric Behavioral Health Medication Initiative for members < 18 years of age.**

Is the member currently in an acute care setting?

- Yes (Inpatient)  Yes (Community Based Acute treatment)  
 Yes (Partial Hospitalization)  No

For members who are in an acute care setting, please document the outpatient prescriber after discharge.

Prescriber name \_\_\_\_\_ Contact information \_\_\_\_\_

Has the member been hospitalized for a psychiatric condition within the past three months?

- Yes. Please document dates of hospitalization within the past three months. \_\_\_\_\_  
 No

On the current regimen, is the member considered to be a severe risk of harm to self or others?

- Yes. Please provide details. \_\_\_\_\_  
 No

For regimens including an antipsychotic, are appropriate safety screenings and monitoring being conducted (e.g., weight, metabolic, movement disorder, cardiovascular, and prolactin-related effects)?

- Yes  No. Please explain. \_\_\_\_\_

Has informed consent from a parent or legal guardian been obtained? \*  Yes  No

Please indicate prescriber specialty:  Psychiatry  Neurology  Other \_\_\_\_\_

- Specialist consult details (if the prescriber submitting the request is not a specialist)

\_\_\_\_\_  
Name(s) of the specialist(s) \_\_\_\_\_ Date(s) of last visit or consult \_\_\_\_\_

Contact information \_\_\_\_\_

For mid-level practitioners (e.g., nurse practitioners, physician assistants), please provide the name and specialty of the collaborating physician.

---

Please document member custody status.

- Parent/Guardian  Department of Children and Families (DCF)

Please document member placement status.

- Home with Parent/Guardian  Foster Care  Residential Treatment Facility  Uncertain  
 Other \_\_\_\_\_

Please document agency involvement.

- DCF  Department of Mental Health (DMH)  Department of Developmental Services (DDS)  
 Department of Youth Services (DYS)

Is the member/family currently receiving appropriate psychotherapeutic and/or community based services for the targeted clinical mental health related concerns (e.g., Applied Behavioral Analysis, Children's Behavioral Health Initiative, school interventions, specialized placement)?

Yes. Please document details of interventions below, if applicable.  No

Psychiatric care provided is coordinated with other psychotherapeutic and community based services.  Yes  No

\* Sample informed consent form available on the MassHealth PBHMI Information webpage. For additional information go to:

<https://www.mass.gov/info-details/pediatric-behavioral-health-medication-initiative-pbhmi-information>

**Section II. Antidepressant Polypharmacy. Complete this section for all members < 18 years of age, if request will result in prescription of two or more antidepressants ≥ 60 days within a 90-day period.**

Please document complete treatment plan (include all antidepressant agents).

1. Antidepressant name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
2. Antidepressant name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
3. Antidepressant name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
4. Other(s) \_\_\_\_\_

Please document if monotherapy trials (include drug name, dates/duration of use, and outcome) with antidepressants were tried before prescribing polypharmacy with two or more antidepressants in this member.\*

Please document the treatment plans for medication regimen simplification (e.g., dose consolidation, frequency reduction) or medical necessity for continuation of a complex medication regimen. \_\_\_\_\_

\*Attach a letter with additional information regarding medication trials as applicable.

**Section III. Antidepressant Request for Members < six years of age.**

Please document complete treatment plan (include all antidepressant agents with dose/frequency/duration and indication(s) for the requested medication(s)).

Please document any previous medication trial(s). Include the drug name, dates/duration of use, and outcome.\*

Please document clinical rationale for use of an antidepressant for this member < six years of age.

\*Attach a letter with additional information regarding medication trials as applicable.

**Section IV. Multiple Behavioral Health Medications. Complete this section for all members < 18 years of age if request will result in prescriptions of four or more behavioral health medications within a 45-day period. For a complete list of all behavioral health medications, please refer to the MassHealth Pediatric Behavioral Health Medication Initiative.**

Please document complete treatment plan (include all behavioral health agents and indication(s) for each medication(s)).

- 1. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
- 2. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
- 3. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
- 4. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
- 5. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
- 6. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
- 7. Other(s) \_\_\_\_\_

Please document monotherapy trials (include drug name, dates/duration of use, and outcome) tried before prescribing a polypharmacy regimen for this member.\*

\_\_\_\_\_

Please document the treatment plans for medication regimen simplification (e.g., dose consolidation, frequency reduction) or medical necessity for continuation of a complex medication regimen.

\_\_\_\_\_

*\*Attach a letter with additional information regarding medication trials as applicable.*

**Prescriber information**

Last name\* \_\_\_\_\_ First name\* \_\_\_\_\_ MI \_\_\_\_\_

NPI\* \_\_\_\_\_ Individual MH Provider ID \_\_\_\_\_

DEA No. \_\_\_\_\_ Office Contact Name \_\_\_\_\_

Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

E-mail address \_\_\_\_\_

Telephone No.\* \_\_\_\_\_ Fax No.\* \_\_\_\_\_

*\* Required*

**Prescribing provider's attestation, signature, and date**

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

**Signature required** \_\_\_\_\_

Printed name of prescribing provider \_\_\_\_\_ Date \_\_\_\_\_